RAPT Therapeutics to be acquired by GSK for $58/share in all-cash tender offer

RAPT Therapeutics, Inc.

GSK subsidiary will commence tender offer at $58.00 per share in cash within 10 business days.
Company termination fee set at $78.4M; reverse termination fee payable by GSK at $100.8M.
Support agreements cover ~0.25% of outstanding shares; Board recommends tender.
Transaction expected to close by July 19, 2026, subject to HSR clearance and majority tender condition.

Key facts

Extracted from this filing and checked against the source text.

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

RAPT Therapeutics, Inc. entered into Merger Agreement with GlaxoSmithKline LLC, Redrose Acquisition Co., GSK plc (effective 2026-01-19).

Action: entry
Agreement: merger
Counterparty: GlaxoSmithKline LLC, Redrose Acquisition Co., GSK plc
Effective: 2026-01-19

Exact text from the filing

RAPT Therapeutics, Inc., a Delaware corporation (the “ Company ” or “ RAPT Therapeutics ”), entered into an Agreement and Plan of Merger (the “ Merger Agreement ”) by and among the Company, GlaxoSmithKline LLC, a Delaware limited liability company (“ Parent ”), Redrose Acquisition Co., a Delaware corporation and a wholly owned subsidiary of Parent (“ Purchaser ”) and, solely for purposes of providing a guaranty pursuant to Section 8.11 of the Merger Agreement, GSK plc, a public limited company organized under the laws of England and Wales (“ Ultimate Parent ” or “ GSK ”).

View on SEC.gov

292 material agreements filed in the last 30 days. Browse all material agreements →

Source: SEC EDGAR

accession 0001193125-26-015882

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.